Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Plug Power Inc (PLUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Plug Power Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Plug Power Inc trades at $2.44 (market cap $3.46B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | PLUG | |
|---|---|---|
Market Cap | $4.49B | $3.46B |
Sector | Health | Industrials |
52-Week High | $28.06 | $4.14 |
52-Week Low | $20.06 | $1.40 |
Enterprise Value | $3.69B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Plug Power (PLUG) trades at $2.48, down 6.06% today amid sector-wide profit-taking, despite recent operational milestones. The stock shows a bearish technical signal with key resistance at $3.00. Fundamentally, the company reported a net loss of $1.63 billion in 2025 with negative gross and net margins, though it has beaten EPS estimates for three consecutive quarters. Revenue grew to $709.92 million in 2025 from $629 million in 2024, but cash flow remains negative, requiring financing to cover operations.
The outlook is high-risk with a path to profitability projected by 2028, but consistent losses and high cash burn pose significant challenges. Analyst consensus is mixed with a $3.28 price target, offering potential upside, yet investors face substantial execution and funding risks. The stock's viability hinges on successful scaling of hydrogen projects and achieving positive cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
